Mounjaro (tirzepatide): uses, dosing, side effects and cost

Mounjaro is Eli Lilly's once-weekly tirzepatide injection, FDA-approved for type 2 diabetes in adults and children 10 and older, and to lower major cardiovascular risk in adults with type 2 diabetes. It is not approved for weight loss; Zepbound is. It starts at 2.5 mg, tops out at 15 mg, and lists at $1,112.16 a fill.

Quick facts

Active ingredient
Tirzepatide, a dual GIP and GLP-1 receptor agonist
Maker
Eli Lilly and Company
FDA approval
2022 (adults); children 10+ added Dec 2025; heart-risk indication added Aug 2026 (Mounjaro label)
Approved for
Blood sugar control in type 2 diabetes (age 10+); cutting the risk of heart attack, stroke or CV death in adults with type 2 diabetes at high risk
Form
Injection under the skin: single-dose pen, single-dose vial, multi-dose vial or 4-dose KwikPen
How often
Once a week, any time of day, with or without food
Dose strengths
2.5, 5, 7.5, 10, 12.5 and 15 mg; maximum 15 mg weekly in adults and 10 mg in children
Boxed warning
Yes: thyroid C-cell tumors in rats; ruled out if you or a relative has had MTC, or if you have MEN 2
List price
$1,112.16 per fill of 4 pens (Lilly pricing page, checked 5 Oct 2026)
Generic available?
No. Compounded tirzepatide is not a generic and is not FDA-approved

What it is

Mounjaro is the brand name Eli Lilly uses for tirzepatide when it is prescribed for type 2 diabetes. The same molecule is sold as Zepbound for weight management, but the two brands carry different labels, different insurance rules and different savings programs.

It is a clear liquid injected under the skin once a week. The August 2026 label lists four presentations:

  • an autoinjector single-dose pen (0.5 mL per dose)
  • a single-dose vial (0.5 mL)
  • a multi-dose vial holding four 0.6 mL doses
  • a single-patient-use KwikPen holding four doses, primed before each injection

Every presentation comes in six strengths, from 2.5 mg to 15 mg. Mounjaro was first approved in 2022. Its label has since added children aged 10 and older (December 2025) and a cardiovascular indication backed by the SURPASS-CVOT trial (August 2026).

How it works

Tirzepatide activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most older drugs in the class, such as semaglutide, act on GLP-1 alone.

Per the Mounjaro label, the result is that it:

  • boosts first- and second-phase insulin release, only when blood sugar is raised
  • lowers glucagon, cutting fasting glucagon by 28% at 15 mg after 28 weeks
  • improves insulin sensitivity
  • slows stomach emptying, most strongly after the first dose
  • reduces food intake and body weight

A fatty side chain lets tirzepatide attach to blood albumin, and that stretches its half-life to about 5 days. That is why one injection covers a whole week, and why steady levels take about 4 weeks of dosing to reach.

Approved uses

The current Mounjaro label lists two indications:

  1. Blood sugar control, alongside diet and exercise, in adults and in children aged 10 and older with type 2 diabetes.
  2. Reducing major cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes at high risk of them.

Weight loss is not an approved use. Prescribing Mounjaro for weight alone is off-label, and insurers usually decline to pay for it. The tirzepatide brand approved for chronic weight management, and for moderate to severe obstructive sleep apnea in adults with obesity, is Zepbound (Zepbound label). See Zepbound vs Mounjaro for how the two differ.

What the evidence shows

The label rests on the SURPASS program. Results are trial averages, not predictions for one person.

  • SURPASS-1 (40 weeks, no other diabetes drugs): HbA1c fell 1.7 to 1.8 points from a baseline near 8.0%, against 0.1 on placebo. Between 78% and 85% reached an HbA1c under 7%.
  • SURPASS-2 (40 weeks, added to metformin, against semaglutide 1 mg): HbA1c fell 2.0, 2.2 and 2.3 points on 5, 10 and 15 mg, against 1.9 on semaglutide. Weight fell 7.6, 9.3 and 11.2 kg, against 5.7 kg.
  • SURPASS-5 (on basal insulin): HbA1c fell 2.1 to 2.4 points, against 0.9 on placebo.
  • SURPASS-PEDS (99 children aged 10 and older): HbA1c fell 1.8 points more than placebo at 30 weeks, pooling both doses.
  • SURPASS-CVOT (13,299 adults with heart disease, median 210 weeks): first major cardiovascular events hit 12.1% on Mounjaro and 13.0% on dulaglutide (hazard ratio 0.92). That met non-inferiority; superiority was not shown.

Dosing overview

The label starts everyone at 2.5 mg once a week. If more glucose control is needed, the prescriber can raise the dose in 2.5 mg steps, each held at least 4 weeks, up to 15 mg for adults or 10 mg for children. The August 2026 label no longer requires a move to 5 mg at week 4; earlier versions did. A missed dose can be taken within 4 days; after that, skip it.

The full step table, the pediatric limit and what the label says about kidneys, the liver and pregnancy are on the Mounjaro dosage page. Injection steps for each device are in how to use Mounjaro.

Side effects overview

Stomach and gut effects dominate. In the label's placebo-controlled pool (SURPASS-1 and SURPASS-5), nausea hit 12% to 18% of people across the 5 to 15 mg doses, against 4% on placebo, and diarrhea 12% to 17%, against 9%. Decreased appetite, vomiting, constipation, indigestion and stomach pain follow. Most nausea, vomiting and diarrhea came during dose increases and eased over time.

Between 3.0% and 6.6% stopped treatment because of gut effects, against 0.4% on placebo. Serious but less common risks include pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration and serious allergic reactions.

The full rates table, warning signs and practical measures are on the Mounjaro side effects page.

Who should not take it

The label says do not use Mounjaro if you or a family member has had medullary thyroid carcinoma (MTC), if you have MEN 2, or if you have had a serious allergic reaction to tirzepatide or any ingredient.

It is not recommended with severe gastroparesis. Tell your prescriber first if you have had pancreatitis, gallbladder disease or diabetic retinopathy, take insulin or a sulfonylurea, use birth control pills, are pregnant, planning pregnancy or breastfeeding, or have surgery coming up. It is not studied in children under 10. The label adds that the KwikPen is not recommended for self-injection by children or by people with visual impairment, and that no pen should ever be shared.

Cost and access

Lilly lists Mounjaro at $1,112.16 per fill, a 28-day supply of four pens, the same at every strength (Lilly pricing page, checked 5 Oct 2026). With commercial coverage, the Mounjaro Savings Card can bring a 1-, 2- or 3-month fill of single-dose pens to as little as $25; with commercial insurance that does not cover it, as low as $499 a month. Both exclude Medicare and Medicaid and end 31 Dec 2026 (Lilly savings terms, checked 5 Oct 2026). LillyDirect sells single-dose pens self-pay from $499 a month (LillyDirect, checked 5 Oct 2026).

Temi does not fill Mounjaro. For adults whose goal is weight loss, Temi's physicians can review a request for compounded tirzepatide, from $104.99 per 8.5 mg vial in California (usetemi.com/medications/compounded-tirzepatide-injectable, checked 5 Oct 2026). Compounded tirzepatide is not FDA-approved and is not a generic Mounjaro. The Mounjaro cost page has the full table.

More on this medication

  • Mounjaro cost

    List price, savings card limits, LillyDirect self-pay and the monthly and yearly arithmetic, dated.

  • Mounjaro interactions

    Birth control pills, insulin, sulfonylureas, warfarin, alcohol and anesthesia, rated by the label.

  • Mounjaro questions

    Short answers to the questions people ask most, each linked to the page that covers it in full.

  • How to use Mounjaro

    Step-by-step injection for the single-dose pen, the KwikPen and the vial, plus storage.

Frequently asked questions

How long does it take for Mounjaro to work?

Tirzepatide reaches steady levels in the blood after about 4 weeks of weekly doses, per the Mounjaro label, and it lowers both fasting and after-meal glucose. The trials judged HbA1c at 30 to 52 weeks; in SURPASS-1 it fell 1.7 to 1.8 points by week 40, on average. Ask your prescriber when your next HbA1c test is due and what result would prompt a change.

Can you take Mounjaro for weight loss without diabetes?

A prescriber can write it off-label, but weight loss is not an approved Mounjaro use, and insurers commonly refuse to cover it that way. Lilly's savings card also requires a prescription for an approved use. For weight management, the FDA-approved tirzepatide product is Zepbound. Ask your prescriber: "Given my diagnosis, which tirzepatide brand fits the label, and what will my plan cover?"

How much weight do people lose on Mounjaro?

In SURPASS-2, adults with type 2 diabetes on metformin lost an average of 7.6 kg on 5 mg, 9.3 kg on 10 mg and 11.2 kg on 15 mg over 40 weeks, against 5.7 kg on semaglutide 1 mg (Mounjaro label). Those are group averages from a diabetes trial. Individual results vary widely, and Mounjaro is not approved as a weight-loss medicine.

Is Mounjaro insulin?

No. Mounjaro is not insulin and does not replace it. Tirzepatide prompts the pancreas to release more of its own insulin when blood sugar is high and lowers glucagon. People who already use insulin can take both, but the label says to inject them separately, never mixed, and warns that the insulin dose may need lowering to avoid low blood sugar.

Does Mounjaro protect the heart?

Since August 2026, the label includes reducing the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high risk. That rests on SURPASS-CVOT, where first major events occurred in 12.1% on Mounjaro and 13.0% on dulaglutide over a median of about four years. Mounjaro was shown non-inferior to dulaglutide, not superior.

Is there a generic Mounjaro?

No FDA-approved generic tirzepatide exists. Compounded tirzepatide, made by 503A or 503B pharmacies, is sometimes described as generic, but it is not: it is a separate preparation that has not gone through FDA approval and is not the same product as Mounjaro or Zepbound. Ask your prescriber how a compounded product differs before choosing one.

Sources

  1. Mounjaro (tirzepatide) prescribing information, Medication Guide and Instructions for Use (Eli Lilly, revised August 2026) (checked October 5, 2026)
  2. MOUNJARO (tirzepatide) injection, solution: label on DailyMed (NLM), revised 8/2026 (checked October 5, 2026)
  3. Zepbound (tirzepatide) prescribing information (Eli Lilly, revised August 2026) (checked October 5, 2026)
  4. Mounjaro cost information: list price per fill (Lilly) (checked October 5, 2026)
  5. Mounjaro Savings Card eligibility, terms and conditions (Lilly) (checked October 5, 2026)
  6. Mounjaro single-dose pen self-pay prices, LillyDirect (checked October 5, 2026)
  7. Compounded tirzepatide injection: prices and pharmacies, Temi (checked October 5, 2026)

Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.

Get started

Start online, and a licensed physician reviews your request

A short online questionnaire is the first step. No appointments and no insurance needed.

A licensed physician reviews every request. Nothing on this page is a prescription.

The revolution will be emailed.

Once a week, roughly.

We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy